X
Search Filters
Format Format
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
humans (24) 24
female (22) 22
index medicus (21) 21
middle aged (21) 21
male (18) 18
adult (16) 16
aged (15) 15
cancer (13) 13
oncology (13) 13
breast cancer (11) 11
chemotherapy (10) 10
quality of life (10) 10
treatment outcome (10) 10
health care sciences & services (9) 9
care and treatment (8) 8
patients (8) 8
young adult (8) 8
management (7) 7
adolescent (6) 6
antineoplastic agents - therapeutic use (6) 6
lung cancer (6) 6
medicine, general & internal (6) 6
metastasis (6) 6
retrospective studies (6) 6
therapy (6) 6
analgesics, opioid - adverse effects (5) 5
constipation - chemically induced (5) 5
metastatic breast cancer (5) 5
pharmacology & pharmacy (5) 5
physicians (5) 5
united states (5) 5
advanced breast cancer (4) 4
aged, 80 and over (4) 4
analysis (4) 4
antineoplastic combined chemotherapy protocols - therapeutic use (4) 4
breast neoplasms - pathology (4) 4
cancer therapies (4) 4
carcinoma, non-small-cell lung - drug therapy (4) 4
constipation (4) 4
costs (4) 4
crizotinib (4) 4
endocrine therapy (4) 4
epidermal growth factor (4) 4
fatigue (4) 4
fulvestrant (4) 4
leukemia (4) 4
lung neoplasms - drug therapy (4) 4
medical research (4) 4
medicine, experimental (4) 4
naltrexone - analogs & derivatives (4) 4
naltrexone - therapeutic use (4) 4
oncology, experimental (4) 4
pain (4) 4
pain medicine (4) 4
palbociclib (4) 4
protein kinase inhibitors - therapeutic use (4) 4
quaternary ammonium compounds - therapeutic use (4) 4
real-world (4) 4
research (4) 4
surveys and questionnaires (4) 4
symptoms (4) 4
womens health (4) 4
advanced (3) 3
age (3) 3
analgesics, opioid - therapeutic use (3) 3
anesthesia & perioperative care (3) 3
antineoplastic combined chemotherapy protocols - adverse effects (3) 3
bowel dysfunction (3) 3
breast (3) 3
breast neoplasms - drug therapy (3) 3
chronic myeloid leukemia (3) 3
clinical neurology (3) 3
clinical trials (3) 3
cohort studies (3) 3
constipation - drug therapy (3) 3
controlled-trial (3) 3
cross-sectional studies (3) 3
dasatinib (3) 3
diabetes mellitus, type 2 - drug therapy (3) 3
disease-free survival (3) 3
double-blind method (3) 3
erbb-2 protein (3) 3
gefitinib (3) 3
germany (3) 3
health care costs - statistics & numerical data (3) 3
health services - utilization (3) 3
imatinib (3) 3
imatinib mesylate (3) 3
internal medicine (3) 3
letrozole (3) 3
leukemia, myelogenous, chronic, bcr-abl positive - drug therapy (3) 3
medical records (3) 3
medicine & public health (3) 3
metastases (3) 3
narcotic antagonists - therapeutic use (3) 3
neoplasm staging (3) 3
nilotinib (3) 3
pain - drug therapy (3) 3
palliative care (3) 3
patient satisfaction (3) 3
more...
Language Language
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


The New England Journal of Medicine, ISSN 0028-4793, 06/2013, Volume 368, Issue 25, pp. 2385 - 2394
In a prospective, randomized, phase 3 trial of crizotinib as second-line therapy in patients who had disease progression while receiving a platinum-based... 
REARRANGEMENT | MEDICINE, GENERAL & INTERNAL | GEFITINIB | ONCOLOGY | EML4-ALK FUSION GENE | CLINICAL-TRIALS | PHASE-III | LYMPHOMA | OPEN-LABEL | DOCETAXEL | EGFR | Glutamates - therapeutic use | Lung Neoplasms - drug therapy | Pyrazoles - therapeutic use | Glutamates - adverse effects | Guanine - analogs & derivatives | Lung Neoplasms - mortality | Humans | Middle Aged | Male | Antineoplastic Agents - therapeutic use | Protein Kinase Inhibitors - adverse effects | Young Adult | Taxoids - therapeutic use | Pyridines - adverse effects | Antineoplastic Agents - adverse effects | Aged, 80 and over | Adult | Female | Guanine - adverse effects | Guanine - therapeutic use | Taxoids - adverse effects | Pyrazoles - adverse effects | Pyridines - therapeutic use | Kaplan-Meier Estimate | Carcinoma, Non-Small-Cell Lung - mortality | Pemetrexed | Disease-Free Survival | Protein Kinase Inhibitors - therapeutic use | Quality of Life | Aged | Carcinoma, Non-Small-Cell Lung - drug therapy | Tyrosine | Intravenous administration | Biomedical research | Lung cancer | Liver | Fatigue | Chromosome rearrangements | Cancer therapies | Patients | Lymphoma | Metastases | Ovarian cancer | Quality of life | Confidence intervals | Chemotherapy | Dyspnea | Alopecia | Platinum | Lymphomas | Respiration | Pharmaceutical industry | Protein-tyrosine kinase
Journal Article
Supportive Care in Cancer, ISSN 0941-4355, 1/2014, Volume 22, Issue 1, pp. 181 - 187
Journal Article
The New England Journal of Medicine, ISSN 0028-4793, 12/2014, Volume 371, Issue 23, pp. 2167 - 2177
The ALK inhibitor crizotinib as first-line therapy was associated with a significantly better response rate, longer progression-free survival, and greater... 
CRITERIA | MEDICINE, GENERAL & INTERNAL | GEFITINIB | THERAPY | CISPLATIN | ADENOCARCINOMA | PHASE-III | KINASE | ANAPLASTIC LYMPHOMA | QLQ-C30 | PLUS | Lung Neoplasms - drug therapy | Pyrazoles - therapeutic use | Guanine - analogs & derivatives | Lung Neoplasms - mortality | Humans | Middle Aged | Antineoplastic Combined Chemotherapy Protocols - adverse effects | Male | Protein Kinase Inhibitors - adverse effects | Cisplatin - administration & dosage | Pyridines - adverse effects | Receptor Protein-Tyrosine Kinases - antagonists & inhibitors | Adult | Female | Pyrazoles - adverse effects | Pyridines - therapeutic use | Kaplan-Meier Estimate | Carboplatin - administration & dosage | Adenocarcinoma - drug therapy | Carcinoma, Non-Small-Cell Lung - mortality | Pemetrexed | Disease-Free Survival | Antineoplastic Combined Chemotherapy Protocols - therapeutic use | Protein Kinase Inhibitors - therapeutic use | Glutamates - administration & dosage | Aged | Carcinoma, Non-Small-Cell Lung - drug therapy | Adenocarcinoma - mortality | Guanine - administration & dosage | Appetite | Edema | Inhibitor drugs | Intravenous administration | Biomedical research | Lung cancer | Diarrhea | Non-small cell lung carcinoma | Fatigue | Nausea | Metastasis | Patients | Cisplatin | Quality of life | Chemotherapy | Lungs | Platinum | Vomiting | Comparative studies | Carboplatin
Journal Article
Breast Cancer Research and Treatment, ISSN 0167-6806, 11/2017, Volume 166, Issue 1, pp. 167 - 177
Journal Article
Clinical Therapeutics, ISSN 0149-2918, 08/2017, Volume 39, Issue 8, p. 1719
To access, purchase, authenticate, or subscribe to the full-text of this article, please visit this link: http://dx.doi.org/10.1016/j.clinthera.2017.07.009... 
Medical research | Care and treatment | Chemotherapy | Epidermal growth factor | Analysis | Medicine, Experimental | Breast cancer | Patient satisfaction | Metastasis | Cancer
Journal Article
Journal of Clinical Oncology, ISSN 0732-183X, 05/2016, Volume 34, Issue 15_suppl, pp. 554 - 554
Journal Article
Future Oncology, ISSN 1479-6694, 01/2019, Volume 15, Issue 2, pp. 141 - 150
Aim: To understand treatment satisfaction in patients with advanced or metastatic breast cancer receiving palbociclib plus an aromatase inhibitor or... 
letrozole | patient satisfaction | CDK4/6 | hormone receptor-positive | fulvestrant | metastatic breast cancer | aromatase inhibitors | estrogen receptor antagonist | advanced breast cancer | palbociclib | SURVIVAL | PATIENT PREFERENCES | CHEMOTHERAPY | DECISIONS | ONCOLOGY
Journal Article
Journal of Clinical Oncology, ISSN 0732-183X, 05/2018, Volume 36, Issue 15_suppl, pp. e13026 - e13026
Journal Article
Journal of Clinical Oncology, ISSN 0732-183X, 05/2018, Volume 36, Issue 15_suppl, pp. e13041 - e13041
Journal Article
Future Oncology, ISSN 1479-6694, 02/2019, Volume 15, Issue 6, pp. 611 - 623
Aim: To understand the treatment patterns and outcomes for stage IV squamous cell carcinoma of the head and neck, patients receiving second-line or later drug... 
metastatic head and neck cancer | real-world | advanced/metastatic | squamous cell carcinoma | metastatic | ALCOHOL | ONCOLOGY | advanced | HPV-ASSOCIATED HEAD | RISK | CANCER
Journal Article
Journal Article
American Journal of Gastroenterology, ISSN 0002-9270, 09/2007, Volume 102, p. S440
Journal Article
Journal of Pain, ISSN 1526-5900, 2011, Volume 12, Issue 5, pp. 554 - 562
Journal Article